Patents Assigned to Prochon Biotech Ltd.
  • Publication number: 20180127475
    Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides comprising a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions comprising same and methods for use thereof.
    Type: Application
    Filed: December 12, 2017
    Publication date: May 10, 2018
    Applicants: PROCHON BIOTECH LTD., HEPACORE LTD.
    Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
  • Patent number: 9862753
    Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 polypeptides comprising a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions comprising same and methods for use thereof.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: January 9, 2018
    Assignees: PROCHON BIOTECH LTD., HEPACORE LTD
    Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
  • Patent number: 9487568
    Abstract: A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal FGF receptors or a skeletal disorder; or (iii) having dysplasic bone. The method includes administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a fibroblast growth factor 9 (FGF-9) variant comprising at least one amino acid substitution in the beta 8-beta 9 loop, wherein said FGF-9 variant incorporates one of the amino acid sequences set forth in SEQ ID NO: 11, 13, 14, 15, 16 or 17.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: November 8, 2016
    Assignee: PROCHON BIOTECH LTD.
    Inventors: Oren Bogin, Avner Yayon
  • Patent number: 8962556
    Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides that include a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions of the same and methods for use thereof.
    Type: Grant
    Filed: October 7, 2007
    Date of Patent: February 24, 2015
    Assignee: Prochon Biotech Ltd.
    Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
  • Patent number: 8940888
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: January 27, 2015
    Assignee: Prochon Biotech Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
  • Patent number: 8916522
    Abstract: A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal FGF receptors or a skeletal disorder; or (iii) having dysplasic bone. The method includes administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a fibroblast growth factor 9 (FGF-9) variant comprising at least one amino acid substitution in the beta 8-beta 9 loop, wherein the FGF-9 variant incorporates one of the amino acid sequences set forth in SEQ ID NO: 11, 13, 14, 15, 16 or 17.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: December 23, 2014
    Assignee: ProChon Biotech Ltd.
    Inventors: Oren Bogin, Avner Yayon
  • Publication number: 20140005141
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Application
    Filed: August 29, 2013
    Publication date: January 2, 2014
    Applicants: Bio-Technology General (Israel) Ltd., Prochon Biotech Ltd.
    Inventors: Boaz AMIT, Avraham Wortzel, Avner YAYON
  • Patent number: 8618258
    Abstract: Methods for treating diseased or injured tissue by implanting into the tissue at a site of the disease or injury a porous freeze-dried fibrin matrix formed from plasma proteins. The proteins include fibrinogen cleaved by the action of thrombin at varying concentrations sufficient to cleave the fibrinogen and Factor XIII. The matrix has less than 10% residual moisture and is devoid of exogenous anti-fibrinolytic agents, plasminogen and of organic chelating agents. Alternatively, the plasma proteins comprise partially purified plasma proteins that are devoid of plasminogen.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: December 31, 2013
    Assignee: Prochon Biotech Ltd.
    Inventors: Avner Yayon, Malkit Azachi, Micha Gladnikoff
  • Publication number: 20130338070
    Abstract: A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal FGF receptors or a skeletal disorder; or (iii) having dysplasic bone. The method includes administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a fibroblast growth factor 9 (FGF-9) variant comprising at least one amino acid substitution in the beta 8-beta 9 loop, wherein said FGF-9 variant incorporates one of the amino acid sequences set forth in SEQ ID NO: 11, 13, 14, 15, 16 or 17.
    Type: Application
    Filed: July 30, 2013
    Publication date: December 19, 2013
    Applicant: ProChon Biotech, Ltd.
    Inventors: Oren BOGIN, Avner YAYON
  • Patent number: 8609823
    Abstract: The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: December 17, 2013
    Assignee: ProChon Biotech, Ltd.
    Inventors: Oren Bogin, Avner Yayon
  • Patent number: 8524885
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: September 3, 2013
    Assignees: Prochon Biotech Ltd., Bio-Technology General (Israel) Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
  • Publication number: 20120219534
    Abstract: Methods for treating diseased or injured tissue by implanting into the tissue at a site of the disease or injury a porous freeze-dried fibrin matrix formed from plasma proteins. The proteins include fibrinogen cleaved by the action of thrombin at varying concentrations sufficient to cleave the fibrinogen and Factor XIII. The matrix has less than 10% residual moisture and is devoid of exogenous anti-fibrinolytic agents, plasminogen and of organic chelating agents. Alternatively, the plasma proteins comprise partially purified plasma proteins that are devoid of plasminogen.
    Type: Application
    Filed: May 7, 2012
    Publication date: August 30, 2012
    Applicant: PROCHON BIOTECH LTD.
    Inventors: Avner Yayon, Malkit Azachi, Micha Gladnikoff
  • Publication number: 20120214739
    Abstract: The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.
    Type: Application
    Filed: January 11, 2012
    Publication date: August 23, 2012
    Applicant: PROCHON BIOTECH, LTD.
    Inventors: Oren Bogin, Avner Yayon
  • Patent number: 8193317
    Abstract: Methods for producing porous freeze-dried fibrin matrices substantially devoid of external anti-fibrinolytic agents. Resilient matrices, also known as sponges, that are particularly beneficial for supporting three dimensional cell growth are obtained from plasma proteins substantially devoid of plasminogen or from partially purified plasma proteins, thus obviating the need for exogenous anti-fibrinolytic agents. Furthermore, incorporation of glycosaminoglycans and bioactive agents during the formation of the matrix results in a sponge having advantageous biological, mechanical and physical properties. The compositions made by the method of the present invention are useful clinically or as cell-bearing implants.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: June 5, 2012
    Assignee: ProChon Biotech Ltd.
    Inventors: Avner Yayon, Malkit Azachi, Micha Gladnikoff
  • Patent number: 8119783
    Abstract: The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: February 21, 2012
    Assignee: ProChon Biotech Ltd.
    Inventors: Oren Bogin, Avner Yayon
  • Patent number: 7714107
    Abstract: The present invention relates to porous freeze-dried fibrin matrices substantially devoid of external anti-fibrinolytic agents, and methods of producing such matrices. Resilient matrices, also known as sponges, that are particularly beneficial for supporting three dimensional cell growth are obtained from plasma proteins substantially devoid of plasminogen or from partially purified plasma proteins, thus obviating the need for exogenous anti-fibrinolytic agents. Furthermore, incorporation of glycosaminoglycans and bioactive agents during the formation of the matrix results in a sponge having advantageous biological, mechanical and physical properties. The compositions of the present invention are useful clinically, without cells or as a cell bearing implants.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: May 11, 2010
    Assignee: ProChon Biotech Ltd.
    Inventors: Avner Yayon, Malkit Azachi, Micha Gladnikoff
  • Patent number: 7563769
    Abstract: The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: July 21, 2009
    Assignee: ProChon Biotech, Ltd.
    Inventors: Oren Bogin, Avner Yayon
  • Publication number: 20090149419
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Application
    Filed: March 6, 2007
    Publication date: June 11, 2009
    Applicants: PROCHON BIOTECH LTD., Bio-Technology General (Israel) Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
  • Publication number: 20080194682
    Abstract: The present invention discloses pharmaceutical compositions for the treatment of skeletal dysplasias, comprising as an active ingredient at least one natriuretic peptide. Unexpectedly, it has been shown that the natriuretic factors may be effective for bone elongation in situations of abnormal bone growth especially for achondroplasia. The effects of the natriuretic peptide may be further enhanced by prolonging its residence time or action at the target site.
    Type: Application
    Filed: August 17, 2007
    Publication date: August 14, 2008
    Applicant: ProChon Biotech Ltd.
    Inventors: Myriam Golembo, Avner Yayon
  • Patent number: 7335508
    Abstract: The present invention relates to porous freeze-dried plasma protein matrices having an open channel structure and a concentration gradient of plasma proteins crosslinked by the action of thrombin, and methods of producing said matrices. The compositions of the present invention are useful clinically, per se or as cell-bearing implants.
    Type: Grant
    Filed: July 22, 2004
    Date of Patent: February 26, 2008
    Assignee: ProChon Biotech Ltd.
    Inventors: Avner Yayon, Hilla Barkay, Malkit Azachi